bullish

Hanmi Pharm

Hanmi Pharm (128940 KS): Strong Base Business; Innovative Biologic Drug Commercialized in US

274 Views26 Mar 2023 18:05
Hanmi reported record high revenue in 2022, driven by strong performance of flagship drugs. The US launch of new biologic drug using Hanmi’s proprietary technology proves the company’s R&D prowess.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
x